Benchmark Maintains Buy on Nutex Health, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bill Sutherland has maintained a Buy rating on Nutex Health (NASDAQ:NUTX) and raised the price target from $30 to $45.
August 21, 2024 | 2:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bill Sutherland has maintained a Buy rating on Nutex Health and increased the price target from $30 to $45, indicating a positive outlook.
The Buy rating and increased price target from a reputable analyst suggest confidence in Nutex Health's future performance, likely leading to positive investor sentiment and potential stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100